Myriad Genetics reported $-17800000 in EBIT for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Ebit Change
Accelerate Diagnostics AXDX:US -17989000 2.09M
Agilent A:US $ 434M 50M
Becton, Dickinson and BDX:US $ 648M 157M
Bio Rad Laboratories BIO:US $ 120.22M 23.31M
Biocept BIOC:US $ -2707000 68.54K
Bruker BRKR:US $ 86M 17.4M
Danaher DHR:US $ 2205M 33M
Exact Sciences EXAS:US $ -152993000 23.99M
Hologic HOLX:US $ 238.5M 355.4M
Illumina ILMN:US $ 30M 154M
Johnson & Johnson JNJ:US $ 6941M 599M
Mettler Toledo International MTD:US $ 271.73M 42.88M
Myriad Genetics MYGN:US $ -17800000 2.9M
Pacific Biosciences Of California PACB:US $ -67969000 9.55M
Perkinelmer PKI:US $ 300.97M 12.24M
Quest Diagnostics DGX:US $ 388M 137M
Repligen RGEN:US $ 58.99M 1.79M
Thermo Fisher Scientific TMO:US $ 2025M 798M
Veracyte VCYT:US $ -7433000 7.82M
Waters WAT:US $ 199.65M 4.18M